Skip to main content
Fig. 3 | BMC Musculoskeletal Disorders

Fig. 3

From: Safety and efficacy of a single intra-articular injection of a novel enhanced protein solution (JTA-004) compared to hylan G-F 20 in symptomatic knee osteoarthritis: a randomized, double-blind, controlled phase II/III study

Fig. 3

Difference in adjusted mean change from baseline in WOMAC Pain Subscale Score (Full Analysis Set). JTA-100/2, group of patients receiving an injection of JTA-004 with 100 μg clonidine and 20 mg hyaluronic acid; JTA-200/2, group of patients receiving an injection of JTA-004 with 200 μg clonidine and 20 mg hyaluronic acid; JTA-200/4, group of patients receiving an injection of JTA-004 with 200 μg clonidine and 40 mg hyaluronic acid; pooled, group of patients receiving an injection of any formulation of JTA-004; reference, group of patients receiving an injection of the reference treatment (hylan G-F 20); N, number of patients; SE, standard error; WOMAC, Western Ontario McMaster Universities. Panel a: difference at Month 6. Panel b: difference at Month 3. Differences in adjusted mean change from baseline in WOMAC Pain Subscale Score were evaluated using an ANCOVA model with treatment group as fixed factor and baseline value of WOMAC Pain Subscale Score as covariate

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us